ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2172

A Novel Cohort to Assess Longitudinal Glucocorticoid Toxicity in Individuals with Rheumatic Diseases: Objectives, Design, and Initial Baseline Characteristics
Abstract Number: 1646

A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE
Abstract Number: 2569

A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders
Abstract Number: 2401

A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE
Abstract Number: 1385

A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Abstract Number: 0019

A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Abstract Number: 0937

A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis
Abstract Number: 1236

A Novel Role for Artificial Intelligence in Detecting Distinctive Scleroderma Facial Features
Abstract Number: 2083

A Novel Scoring System to Predict a Cancer Development in Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 0021

A Novel Small Molecule Screening Assay Using Normal Human Chondrocytes Toward Osteoarthritis Drug Discovery
Abstract Number: 2594

A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Abstract Number: 2410

A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
Abstract Number: 1778

A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 0879

A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Abstract Number: 0085

A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].